Free Trial

Axsome Therapeutics (AXSM) Stock Price, News & Analysis

$71.55
+0.48 (+0.68%)
(As of 06/12/2024 ET)
Today's Range
$70.11
$72.89
50-Day Range
$65.72
$78.12
52-Week Range
$55.02
$98.40
Volume
736,796 shs
Average Volume
707,417 shs
Market Capitalization
$3.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$122.08

Axsome Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
70.6% Upside
$122.08 Price Target
Short Interest
Bearish
17.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.67mentions of Axsome Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$4.98 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.70) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

113th out of 913 stocks

Pharmaceutical Preparations Industry

42nd out of 429 stocks

AXSM stock logo

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

AXSM Stock Price History

AXSM Stock News Headlines

Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from Mizuho
Why Axsome Therapeutics Stock Is Sinking Today
Axsome Therapeutics, Inc. (AXSM)
15 Most Depressed States in the US
Q1 2024 Axsome Therapeutics Inc Earnings Call
See More Headlines
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Today
6/12/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AXSM
Employees
545
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$122.08
High Stock Price Target
$190.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+70.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$-239,240,000.00
Net Margins
-118.07%
Pretax Margin
-118.71%

Debt

Sales & Book Value

Annual Sales
$251.02 million
Book Value
$4.04 per share

Miscellaneous

Free Float
36,857,000
Market Cap
$3.40 billion
Optionable
Optionable
Beta
1.25
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

AXSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Axsome Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares.
View AXSM analyst ratings
or view top-rated stocks.

What is Axsome Therapeutics' stock price target for 2024?

13 analysts have issued 1-year price objectives for Axsome Therapeutics' shares. Their AXSM share price targets range from $81.00 to $190.00. On average, they anticipate the company's share price to reach $122.08 in the next twelve months. This suggests a possible upside of 70.6% from the stock's current price.
View analysts price targets for AXSM
or view top-rated stocks among Wall Street analysts.

How have AXSM shares performed in 2024?

Axsome Therapeutics' stock was trading at $79.59 at the start of the year. Since then, AXSM shares have decreased by 10.1% and is now trading at $71.55.
View the best growth stocks for 2024 here
.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 8,270,000 shares, an increase of 9.0% from the May 15th total of 7,590,000 shares. Based on an average daily volume of 677,300 shares, the days-to-cover ratio is currently 12.2 days.
View Axsome Therapeutics' Short Interest
.

When is Axsome Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our AXSM earnings forecast
.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its earnings results on Monday, May, 6th. The company reported ($1.09) earnings per share for the quarter, topping analysts' consensus estimates of ($1.20) by $0.11. The firm had revenue of $75 million for the quarter, compared to analysts' expectations of $69.91 million. Axsome Therapeutics had a negative net margin of 118.07% and a negative trailing twelve-month return on equity of 87.17%.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

When did Axsome Therapeutics IPO?

Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.87%), Alethea Capital Management LLC (1.56%), Bellevue Group AG (1.44%), Hood River Capital Management LLC (1.10%), Affinity Asset Advisors LLC (0.29%) and Healthcare of Ontario Pension Plan Trust Fund (0.29%). Insiders that own company stock include Mark Coleman, Mark E Saad, Mark L Jacobson, Nick Pizzie and Roger Jeffs.
View institutional ownership trends
.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXSM) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners